West Pharmaceutical Servs''s Return On Capital Employed Insights
According to Benzinga Pro, during Q2, West Pharmaceutical Servs (NYSE: WST ) earned $188.50 million, a 8.46% increase from the preceding quarter. West Pharmaceutical Servs also posted a total of $771.30 million in sales, a 7.12% increase since Q1. In Q1, West Pharmaceutical Servs earned $173.80 million, and total sales reached $720.00 million. What Is Return On Capital Employed? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, … Full story available on Benzinga.com
West Pharmaceutical Servs''s Return On Capital Employed Insights
According to Benzinga Pro, during Q2, West Pharmaceutical Servs (NYSE: WST ) earned $188.50 million, a 8.46% increase from the preceding quarter. West Pharmaceutical Servs also posted a total of $771.30 million in sales, a 7.12% increase since Q1. In Q1, West Pharmaceutical Servs earned $173.80 million, and total sales reached $720.00 million. What Is Return On Capital Employed? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, … Full story available on Benzinga.com